Utility of Chemoresponse Assay in XXXX Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.

@entity1 @entity632 @entity43 @entity242 @entity5 @entity1138 @entity900 @entity2615 @entity1104 @entity694 @entity420 @entity356
PURPOSE: Our aim was to evaluate the utility of in vitro drug sensitivity testing in @entity1 with peritoneal surface @entity5 undergoing @entity1104 ( @entity1104 ) plus hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: We found data for 27 @entity1 who underwent @entity1104 plus HIPEC from September 2009 to May 2012 and whose @entity5 were submitted for in vitro drug sensitivity (ChemoFx(  )). Intraperitoneal chemotherapy agents included @entity1138 , @entity900  +  @entity632 , or @entity900 alone. RESULTS: There were 12 (44.4  %) appendiceal @entity420 , 5 (18.5  %) @entity694 , 4 (14.8  %) @entity242 , 3 (11.1  %) @entity43 , 2 (7.4  %) @entity2615 , and one (3.7  %) @entity356 . In all, 15 @entity1 (55.5  %) underwent complete cytoreduction (CC   <=  1). Seventeen @entity5 (63  %) displayed in vitro sensitivity to the agents used. Mean overall (OS) and progression-free (PFS) survivals for the entire group were 34.4      4.5  months (median 41  months) and 12.5      2.1  months (median 8  months), respectively. There were no significant differences in OS and PFS for @entity1 whose @entity5 displayed in vitro drug sensitivity versus those whose @entity5 did not (p  =  0.101 and p  =  0.403, respectively). These results also did not differ when evaluating only the @entity1 who underwent complete cytoreduction. In vitro, the drug sensitivity did not correlate with @entity5 pathology or preoperative systemic chemotherapy administration. In vitro drug sensitivity correlated with the drug used at the time of HIPEC (p  =  0.003). None of the @entity5 tested showed in vitro sensitivity to @entity900 and/or @entity632 . Eight nonresponsive @entity5 , however, showed in vitro activity to other agents. CONCLUSIONS: Data indicate a high rate of in vitro resistance to the intraperitoneal chemotherapeutic agents used. In vitro drug sensitivity is not useful in @entity1 undergoing @entity1104 plus HIPEC.
